Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Arrail Group (瑞尔集团) Pre-IPO:  Peer Comp and Thoughts on Valuation

Arrail Group (瑞尔集团) IPO: Downsized Deal Mostly Taken by Cornerstones

Arrail Group (瑞尔集团) IPO Trading: Weak Demand, Rich Valuation

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Health care / Quantitative Analysis

<ul>
<li>Arrail is a leading dental service provider in China. The company is looking to raise up to USD100 m via a Hong Kong listing.</li>
<li>In this note, we look at the company's background, its operation, its financials, and its expansion plan. </li>
<li>We think the company has a decent investor backing and management team.</li>
</ul>


Arrail is a leading dental service provider in China. The company is looking to raise up to USD100 m via a Hong Kong listing.
In this note, we look at the company's background, its operation, its financials, and its expansion plan. 
We think the company has a decent investor backing and management team.


Arrail Group (瑞尔集团) Pre-IPO: Watch the Margins